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Gang Shi1* and Shanling Liu1,3,4,5*Abstract
Background: As an acute-phase protein, serum amyloid A (SAA) is expressed primarily in the liver. However, its
expression in extrahepatic tissues, especially in tumor tissues, was also demonstrated recently. In our study, we
investigated the expression of SAA in uterine cervical carcinomas, and our results suggested its potential as a serum
biomarker.
Methods: Quantitative real-time polymerase chain reaction (RT-PCR), immunohistochemistry (IHC) and
enzyme-linked immunosorbent assay (ELISA) were used to evaluate the SAA gene and protein expression levels in
the tissues and sera of patients with non-neoplastic lesions (NNLs), cervical intraepithelial neoplasia (CIN) and
cervical carcinoma (CC).
Results: Compared with NNLs, the SAA gene (SAA1 and SAA4) expression levels were significantly higher in uterine
CC (mean copy numbers: 138.7 vs. 5.01, P < 0.000; and 1.8 vs. 0.079, P = 0.001, respectively) by real-time PCR. IHC
revealed cytoplasmic SAA protein staining in tissues from adenocarcinoma and squamous cell carcinoma of the
cervix. The median serum concentrations (μg/ml) of SAA were 6.02 in patients with NNLs and 10.98 in patients with
CIN (P = 0.31). In contrast, the median serum SAA concentration was 23.7 μg/ml in uterine CC patients, which was
significantly higher than the SAA concentrations of the NNL group (P = 0.002) and the CIN group (P = 0.024).
Conclusions: Our data suggested that SAA might be a uterine CC cell product. High SAA concentrations in the
serum of CC patients may have a role in monitoring disease occurrence and could have therapeutic applications.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1433263219102962.
Keywords: Uterine cervical carcinoma, Serum amyloid A, Tumor markerIntroduction
Each year, more than 530,000 women develop cervical
carcinoma (CC), and 270,000 die from this disease globally
[1], which makes CC the third most common and the fifth
most lethal cancer worldwide. Based on both clinical and
histopathological variables, uterine cervical diseases are
categorized into three groups: non neoplastic, intraepithe-
lial neoplasia and carcinoma. Carcinoma is further classi-
fied into two main subtypes: cervical adenocarcinomas* Correspondence: gang-shi@163.com; sunny630@126.com
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reproduction in any medium, provided the orand squamous cell carcinoma (SCC). The survival rate for
patients with CC, similar to many other cancers, is also re-
lated to early disease detection. The patient survival rate
depends significantly on the clinical (FIGO: International
Federation of Gynecology and Obstetrics) stage and is as
high as 90% (good) when the disease is diagnosed early
and as low as 15% (poor) when the diagnosis is delayed
[2-4]. Therefore, early diagnosis and treatment could sig-
nificantly increase the survival rates of CC patients and
their quality of life. As oncogenic human papillomavirus
(HPV) can be detected in nearly all CC patients, the role
of HPV in the progression of CC has been determined.
Over the course of years, only a small proportion of
women with a chronic HPV infection will develop cancer,
which may underline the potential diverse patterns of. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pears to be sensitive, it lacks specificity [5-7], and a recent
report indicated that some types of CC, such as minimal
deviation adenocarcinoma, were not associated with high-
risk HPV [8]. Thus, in addition to HPV DNA testing,
the discovery of novel diagnostic and therapeutic markers
against this malignancy should be prioritized.
Serum amyloid A (SAA) is a positive acute-phase protein
with four different isotypes in humans. SAA is generated
primarily by the liver in response to trauma, infection,
inflammation, and even neoplastic stimuli [9]. SAA1
and SAA2 each consist of 122 amino acids, including
signal peptide sequences, and share more than 90%
amino acid identity [10]. In addition, SAA3 is a pseudo-
gene, and SAA4 is constitutively expressed at a constant
level and is thus known as cSAA. The acute-phase SAAs
(aSAA), SAA1 and SAA2, increase in concentration
approximately several hundred-fold in response to
inflammatory stimuli [11,12]. However, recent studies
have revealed other major sources of SAA outside of
the liver: specifically, cancer tissues of the esophagus
[13], lung [14], pancreas [15], ovary [16], and uterine
endometrium [5]. Moreover, recent data suggest that
A-SAA, by activating the transcriptional factor nuclear
factor kappa-B (NFκB) [17-21] and inducing the expression
of matrix metalloproteinases (MMPs) [22-24], could con-
siderably influence carcinogenesis. NFκB is a transcriptional
factor for many functionally heterogeneous genes, notably
the cytokine genes and anti-apoptotic genes. The activation
of these genes could suppress apoptosis [25]. Additionally,
a number of mechanisms have shown that MPPs could
stimulate angiogenesis and activate cell migration.
To the best of our current knowledge, the localized ex-
pression of SAA in CC has not yet been reported. In this
study, using RT-PCR, immunohistochemistry (IHC), and
ELISA, we aimed to examine SAA expression and secre-
tion in human CC.
Materials and methods
Tissues and serum
A total of 31 cervical tissue samples and 138 serum
specimens obtained from West China Second University
Hospital, Sichuan University from March 2011 to
September 2012 were analyzed and segregated into
the following diagnostic groups: non-neoplastic lesion
(NNL), cervical intraepithelial neoplasia (CIN 1, CIN 2, and
CIN 3), and invasive neoplasia (FIGO 2009 stages I and II)
(detailed in Table 1). Freshly frozen biopsies were assessed
using quantitative real-time polymerase chain reaction
(RT-PCR) for SAA expression and were derived from
primary specimens staged according to the FIGO surgical
staging system, including 21 CC and 10 NNL cervical con-
trol samples obtained from hysterectomy specimens from
women of similar ages [respective mean ages of 47.5 ± 3.1(SD) and 42.7 ± 3.2 (SD) years old, respective ranges of
37–64 and 31–64 years old]. Formalin-fixed and paraffin-
embedded cervical tissues were submitted to IHC testing,
including 16 CC [4 adenocarcinoma and 12 squamous
cell carcinoma, mean age 49.8 ± 4.3 (SD) years old,
range 34–65 years old] and 5 NNL cervical control
samples [5 uterine fibroids, mean age 43.6 ± 4.5 years
old, range 31–59 years old]. The demographics and
histological findings of the CC patients were graded
and staged; the types of sections included in this study
are detailed in Table 1. Serum samples measured by
ELISA included the following: 32 women with NNL
diseases [mean age 43.4 ± 8.4 (SD) years old, range 34–
59 years old], 34 women with CIN [mean age 40.3 ± 7.5
(SD) years old, range 31–57 years old], and 72 women with
histologically proven primary uterine cervical carcinoma
[mean age 48.4 ± 8.7 (SD) years old, range 35–63 years old]
(detailed in Table 1). The inclusion and exclusion criteria of
the trial are detailed in Table 2. All samples tested were de-
rived from patients who had provided written informed
consent, and the study was approved by the ethics commit-
tee of West China Second Hospital of Sichuan University.
RNA extraction and quantitative real-time PCR
Total RNA from all primary snap-frozen samples, includ-
ing the 21 CCs and 10 NNL cervical sample controls, was
isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. The purity
and amount of RNA were determined by measuring the
ODs at a ratio of 260 to 280 nm. cDNA was reverse-
transcribed from 1 μg of total RNA using the PrimeScript®
RT reagent kit with gDNA Eraser (Perfect Real-Time)
(Takara Biotechnology, Dalian, China). Quantitative PCR
was performed with a CFX96 Touch Real-Time PCR
Detection System using the manufacturer’s recom-
mended protocol (Bio-Rad Laboratories, Hercules, CA)
to evaluate SAA expression in all the samples. Each re-
action was run in triplicate. Briefly, 2 μl of each cDNA
sample (from a 20-μl total volume) was amplified using
SsoFast EvaGreen® Supermix (BIO-RAD) to produce PCR
products specific for SAA. The primer sequences specific
for the two known human SAA genes, SAA1 and SAA4,
were previously described in [26]. β-2 M served as a house-
keeping gene for standardization. The negative control
included replacement of the cDNA with H2O in the PCR.
SAA immunostaining of formalin-fixed tumor tissues
Formalin-fixed paraffin-embedded NNL cervical control
tissues and tumor tissues were evaluated using standard
immunohistochemical staining for SAA expression. Study
blocks (21 samples, including 16 CCs and 5 NNL cervical
control samples) were selected after histopathologic review
by surgical pathologists. The most representative block
was selected for each specimen. Briefly, deparaffinized
Table 1 Clinicopathological characteristics of patients enrolled in this study
Characteristics RT-PCR IHC ELISA
Number Percentage (%) Number Percentage (%) Number Percentage (%)
Histological type
Adenocarcinoma 2 6.4 4 19.0 6 4.3
Squamous cell carcinoma 19 61.3 12 57.1 66 47.8
CIN 0 0 34 24.6
Uterine fibroids 10 32.3 5 23.9 21 15.2
Endometrial polyps 0 0 5 3.6
Ovarian cysts 0 0 6 4.3
Grade of tumor
Well differentiated 2 9.5 4 25 19 26.4
Moderately differentiated 2 9.5 5 31.3 11 15.3






Ia 0 2 12.5 3 4.1
Ib 12 57.1 6 37.5 30 41.7
IIa 6 28.6 5 31.3 30 41.7
IIb 3 14.3 3 18.7 9 12.5
Lymph node metastasis
Negative 10 47.6 5 31.3 21 29.2
Positive 11 52.4 11 68.7 51 70.8
NAC, Indicate neoadjuvant chemotherapy; CIN, Cervical intraepithelial neoplasias; SD, Standard deviation.
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the manufacturer’s instructions (DAKO Corporation;
Carpinteria, CA). Eighty microliters of ready-to-use anti-
bodies (clone mc1, DAKO) was used in each slice, which
was then incubated for 2 hours at room temperature.
The slides were washed with PBS and then incubated
(1 hour at room temperature) with goat anti-mouse bio-
tinylated secondary antibody (ZSGB-BIO, Beijing, China).Table 2 Criteria for inclusion and exclusion in this trial
Inclusion criteria Exclusion criteria
Newly diagnosed, pathologically
confirmed diagnosis of CC
Chemotherapy, biologic therapy
or any other investigational drug
for any reason within 28 days prior
to sampling
No previous chemotherapy or
radiation therapy
Major surgical procedure, or
significant traumatic injury
within 28 days prior to sampling
No concurrent disease(s) Pregnancy
Signed informed client consentThe colorimetric readout was developed in 8 minutes using
a DAB kit (ZSGB-BIO), followed by counterstaining
with hematoxylin. The anti-SAA monoclonal antibody
used (clone mc1, DAKO) was directed against amyloid
fibril protein AA. The specificity of this antibody was
previously described in [14]. For the negative control,
the primary antibodies were replaced with PBS. Liver
sections were used as positive controls.
Measurement of SAA concentrations in serum samples
The SAA serum levels were determined using an SAA1-
specific ELISA kit (Invitrogen). Samples collected before
surgery were centrifuged at 1,600 × g for 15 min within
2 hours of collection and stored at −80°C until analysis.
All the serum samples were thawed on ice for 40 minutes,
allowed to reach room temperature, and diluted 200-fold
with the standard diluent buffer provided in the kit. ELI-
SAs were then performed according to the manufacturer’s
instructions. After adding the Stop Solution to each well,
the solution color changed from blue to yellow. The ab-
sorbance of each well was read on a Bio-Rad Model-680
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450 nm to determine the SAA concentrations. The plate
was read within 30 minutes after adding the Stop Solution.
All specimens were tested in replicate wells. The results
were reported as the means of the replicates. A standard
curve was run in each assay.
Statistical analysis
For quantitative real-time PCR, the fold change of mRNA
was calculated using the 2ΔΔCt method (ΔCt = the differ-
ence in threshold cycles for the target and β-2 M), with
normalization to the level of β-2 M, and the results were
compared for differences using the equal-variance t-test
for the CC samples versus the NNL cervical samples. All
images were captured using a Nikon Eclipse 55i microscope
(Minato-ku, Japan), and the different expression levels
among cervical tissues were analyzed using IHC. SAA
serum concentrations among the different groups of
patients (i.e., NNL diseases, cervical intraepithelial
neoplasias, and cervical carcinomas, with different de-
grees of differentiation) were calculated from standard
curves and summarized as medians and ranges. The
differences were compared using the Wilcoxon-Kruskal-
Wallis Test. SPSS 16 (SPSS Inc., Chicago, IL) for the
statistical analysis. A 5% significance level was used for
all statistical comparisons.
Results
SAA expression in snap-frozen cervical carcinoma tissues
by quantitative real-time PCR
The expression of SAA1 was remarkably up-regulated
in CC tissues compared with NNL cervical tissues. SAA4
had an expression pattern similar to that of SAA1
(Figure 1; Table 3). The relative threshold cycle (ΔCt)
values of SAA1 and SAA4 in the NNL cervical control
samples were 7.64 ± 2.02 and 13.63 ± 3.11 (mean ± standard
error), respectively, and the ΔCt values in the CC samples
were 2.85 ± 3.02 and 9.12 ± 3.05 (mean ± standard error),
respectively (Table 3). Using the 2ΔΔCt method, the SAA1
and SAA4 expression levels in the CC samples were 27.67
(Table 3, P < 0.000) and 22.87 (Table 3, P = 0.001) times
higher, respectively, than in NNL control tissues. Figure 2
shows weak to barely detectable SAA1 and SAA4 gene
expression in NNL cervical tissues and strong expres-
sion in carcinoma tissues by electrophoresis on a 2%
agarose gel. The control β2M gene was expressed at
comparable levels in all samples.
SAA expression by immunohistochemistry in cervical
carcinoma tissues
Figure 3 shows positive cytoplasmic SAA protein expres-
sion levels in all cervical carcinoma tissues, as detected by
IHC. In contrast, no SAA positivity was detected in NNL
cervical tissues (Figure 3). However, there were differencesin the staining patterns between squamous cell carcinoma
and adenocarcinoma and between stages I and II. Normal
liver tissue (i.e., the positive control) was strongly positive
for SAA expression (Figure 3).
Serum SAA concentrations in cervical carcinoma, cervical
intraepithelial neoplasia, and benign disease patients
Our data demonstrate that the SAA serum expression
levels were comparable between patients with CIN and
NNL gynecologic diseases (Figure 4; Table 4). The me-
dian SAA serum levels were 9 for the 32 control patients
with NNL gynecologic disease and 14 for the 35 patients
with CIN; their distributions were not significantly dif-
ferent (P = 0.31, Table 4 and Figure 4a). In contrast, the
serum SAA values from CC patients were significantly
higher than the values in the NNL group (P = 0.002) and in
the CIN group (P = 0.024, Table 4 and Figure 4a). However,
no differences were observed between different clinical
stages (stages I and II, P = 0.483, Table 4 and Figure 4b)
and histological types (adenocarcinoma and squamous
cell carcinoma, P = 0.626, Table 4 and Figure 4c).
Discussion
In this study, using immunohistochemistry and real-time
PCR analyses, we demonstrated the local over-expression
of SAA at the protein and mRNA levels in human uterine
cervical carcinomas, which may suggest that the tumor
cells are the predominant source of SAA in cancer pa-
tients. In addition, we evaluated SAA levels in 138 serum
samples derived from patients with NNL diseases of the
cervix, CIN (precursor of cancer), and uterine cervical car-
cinomas and found that the circulating levels of SAA
gradually increased with the carcinogenesis and progres-
sion of cervical cancer. Our findings suggest that there is a
critical role for SAA in cervical carcinogenesis and may
provide a promising target for future clinical therapy and
postoperative surveillance.
Our findings indicate that the elevated SAA levels in
local tissues and sera were due to its expression and
secretion from CC cells. First, we reported a high SAA
gene expression level in CC cases. By real-time PCR,
the SAA1 and SAA4 mRNA expression levels were sig-
nificantly higher in CC tissues than in NNL cervical
tissues, with 27.7- and 22.8-fold higher copy numbers,
respectively. Additionally, cytoplasmic positivity for
SAA was detected by IHC in all CC-derived tissues,
which verified that the presence of SAA mRNA is ac-
companied by SAA protein synthesis. Furthermore, in
addition to the high levels of SAA gene expression, we
detected high levels of circulating SAA. Additionally,
in the limited number of patients undergoing chemo-
therapy, the serum levels of SAA were low, which
could indirectly confirm that CC cells could secrete
and express SAA.
Table 3 SAA mRNA expression by RT-PCR
Variable No ΔCt (Mean ± SD)
SAA1 SAA4
NNL tissues 10 7.64 ± 2.02 13.63 ± 3.11
CC tissues 21 2.85 ± 3.02 9.12 ± 3.05
ΔΔCt 4.79 (P < 0.000) 4.51 (P = 0.001)
2ΔΔCt 27.67 22.78
SD, Standard deviation; NNL, Non neoplastic lesion; CC, Cervical carcinoma;
ΔCt, The difference in threshold cycles for the target gene; ΔΔCt, The
difference in ΔCt values for the target gene.
a
b
Figure 1 mRNA expression of SAA1 and SAA4 in freshly frozen biopsies. Expression of SAA1 (a) and SAA4 (b) by quantitative real-time
polymerase chain reaction (RT-PCR) in 10 non neoplastic lesion cervical control samples and 21 cervical carcinoma freshly frozen biopsies are shown.
The vertical axis represents the relative values of threshold cycle corrected with β2M (2-ΔCt). Values are means ± SD of triplicate measurement.
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ciated with CC progression. Notably, although there were
no significant differences between the serum levels of the
patients harboring NNL gynecological diseases and CIN
and patients with stage I and II CC, the mean SAA serum
levels of these groups were gradually increased with
disease progression (Figure 4b; Table 4), with the high-
est serum levels in the stage II group. Cocco [5] and
Urieli-Shoval [16] recently reported on SAA expression in
two major gynecological cancers, endometrial endometrioid
Figure 2 SAA mRNA expression by electrophoresis. Representive SAA1 and SAA4 PCR fragments were analyzed on a 2% agarose gel. In each
8 lanes, the first four were derived from different cervical carcinoma tissues and the rest were from non neoplastic lesion cervical tissues. Markers
of a DNA ladder (50-bp steps) are shown in lane M. Using primers for SAA1, SAA4, and the control gene β-2 M analysis 10 benign cervical and 21
cervical carcinomas (2 adenocarcinomas and 19 squamous cell carcinomas) patients by RT-PCR.
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in situ hybridization and IHC, they demonstrated local
and differential expression of SAA in human endomet-
rial carcinoma and ovarian epithelial tumors compared
with normal endometrial and ovarian epithelial tissues.
Furthermore, they demonstrated that there was progres-
sively higher SAA positivity through the different stages
of dysplasia to overt carcinoma. Although the biological
importance of SAA in cancer patients is not well under-
stood, these findings in human endometrial endometrioid
carcinoma and ovarian epithelial tumors, combined with
our results in uterine cervical carcinoma, appear to suggest
a novel role for SAA autocrine production in gynecological
tumorigenesis and progression.
Several studies have proposed that SAA protein func-
tions are relevant to tumor cell invasion and metastasis.
First, SAA may influence carcinogenesis. As mentioned
above, SAA could activate the transcriptional factor NFκB,Figure 3 SAA protein expression by IHC. IHC demonstrating SAA protei
with monoclonal anti-SAA antibodies. The reddish-brown staining represen
neoplastic lesion cervical tissue. The tumoral epithelium stained moderate
squamous carcinoma tissues stained moderate and focal. (d) and diffuse (e
control (f) Liver. Original magnification x400 (a-f).which could suppress apoptosis. Given that inflammation
has recently been proposed to be associated with tumori-
genesis [27,28], SAA may play a role in local inflammation
in the microenvironment of the malignant tissue by indu-
cing the production of pro-inflammatory cytokines; tumor
necrosis factor-α (TNFα); interleukin-1b (IL-1); and the
chemokines CCL1, CCL3, and CCL4 [29-31]. SAA1 also
promotes the up-regulation of genes involved in phagocyt-
osis, anti-apoptosis, and tissue remodeling [26]. Second,
as it does for human leukocytes [32,33], SAA may induce
the adhesion of tumor cells and may enhance tumor cell
survival and proliferation, as shown in rheumatoid arthritis
[34-36]. Third, SAA may enhance tumor cell invasion
and metastatic spread by becoming directly involved in
enhancing the activity of matrix degrading enzymes
(MMP/TIMP-1) and by increasing TNFα production in
and through its association with collagen cleavage in vivo
[22,35,36]. Finally, SAA-derived peptides may inhibit tumorn expression in cervical carcinomas. The sections were immunostained
ts positive SAA protein signal; counterstaining is light blue. (a) Non
to strong and focal. (b, c) Adenocarcinoma. The stage I cervical
).Stage II. Strong cytoplasmic SAA positivity was evident in the positive
Figure 4 (See legend on next page.)
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Figure 4 SAA serum levels by ELISA. (a) SAA serum levels in patients with cervical carcinoma. Serum levels of SAA were measured in patients
with cervical pathologies classified as follows: (1) Non neoplastic lesion gynecologic diseases (n32), (2) cervical intraepithelial dysplasia (n35), (3)
cervical carcinoma (n72). (b) SAA levels in cervical carcinoma with different degrees of stage (ie, 34 stages I, 37 stages II) are shown. Data are
presented as mean ± standard deviation of mean. (c) SAA levels in cervical carcinoma with different histological types (ie, 66 squamous cell
carcinomas, 6 adenocarcinomas) are shown.
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for T-lymphocytes and platelets [37,38]. Whether any
of these possibilities have relevance in the development
of human CC requires further investigation.
To the best of our knowledge, this is the first system-
atic study describing the expression of SAA in human
CC tissues. We have demonstrated that SAA mRNA and
protein expression levels were high in cervical tumors
compared with NNL cervical tissues. In addition, high
concentrations of SAA were detected in the sera of CC
patients. Given that an HPV screening assay is not in
itself sufficient for identifying cervical cancer, some
other methods, such as the novel biomarker Lam-5,
which is detected in cervical adenocarcinoma [39], and
the hTERC amplification test [40], have been reported.
Although our data are preliminary and exploratory and
require further validation in future studies, they support
the hypothesis that SAA may be involved in cervical
tumorigenesis and may be a candidate tissue and serum
biomarker and perhaps a therapeutic target. Furthermore,
combining the new assays described above may constitute
a more useful method for monitoring cervical cancer.
However, although our data on the SAA serum levels
reveal an obviously increasing trend in patients with
NNL cervical diseases, CIN, and stage I and II cervical





Stage I 33 22.7
Stage II 39 24.3
Adenocarcinoma 6 20.2
Squamous cell carcinoma 66 25.9
Pairwise Comparison P
NNL versus CIN 0.31
NNL versus stage I 0.002
CIN versus stage I 0.024
Stage I versus stage II 0.483
Adenocarcinoma and squamous cell carcinoma 0.626
NNL Indicates non-neoplastic lesion; CIN Indicates cervical intraepithelial
neoplasias; CC Cervical carcinoma; SD, Standard deviation; P Values are from
2-sided Wilcoxon-Kruskal-Wallis tests for the indicated comparisons.II carcinoma groups lack statistical significance. Therefore,
larger studies that include more patients would be neces-
sary to confirm this hypothesis that SAA levels increase
with increasing disease progression. Additionally, which
up- or downstream signaling pathways could be useful for
CC treatment remains unknown. Future studies that in-
vestigate the specific mechanism of SAA secretion in CC
cells may help clarify this issue.
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